Targeted alpha-therapy for control of micrometastatic prostate cancer.

about

Targeted α-particle therapy of bone metastases in prostate cancer Treatment landscape of metastatic prostate cancer: the role of radium-223.

P2860

Q37417656-8F2DB4D5-3177-411C-8B91-9F9EAC2F499F Q38885735-4E88E0A7-0929-49C7-8EC8-BF33AC67FFA7

P2860

Targeted alpha-therapy for control of micrometastatic prostate cancer.

Item

http://www.wikidata.org/entity/Q35782949

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@ast

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@en

type

Item

label

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@ast

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@en

prefLabel

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@ast

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@en

P1476

Targeted alpha-therapy for control of micrometastatic prostate cancer.

@en

P2093

Barry J Allen

http://www.w3.org/2001/XMLSchema#string

Pamela J Russell

http://www.w3.org/2001/XMLSchema#string

Yong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Kinase inhibitors in cancer therapy: a look ahead.

The emerging role of radioimmunotherapy in haematological malignancies.

Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.

Tumor therapy with targeted atomic nanogenerators.

The urokinase-type plasminogen activator system in prostate cancer metastasis.

Progress in immunoconjugate cancer therapeutics.

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

P304

459-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.4.3.459

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15161444

http://www.w3.org/2001/XMLSchema#string

Targeted alpha-therapy for control of micrometastatic prostate cancer.

about

P2860

P2860

Targeted alpha-therapy for control of micrometastatic prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698